A novel treatment approach utilizing helical tomotherapy for partial breast irradiation for patients with early-stage breast cancer is described. This technique may serve as an alternative to high dose-rate (HDR) interstitial brachytherapy and standard linac-based approaches. Through helical tomotherapy, highly conformal irradiation of target volumes and avoidance of normal sensitive structures can be achieved. Unlike HDR brachytherapy, it is noninvasive. Unlike other linac-based techniques, it provides image-guided adaptive radiotherapy along with intensity modulation. A treatment planning CT scan was obtained as usual on a post-lumpectomy patient undergoing HDR interstitial breast brachytherapy. The patient underwent catheter placement for HDR treatment and was positioned prone on a specially designed position-supporting mattress during CT. The planning target volume (PTV) was defined as the lumpectomy bed plus a 20 mm margin.
Introduction
Breast cancer is the most common non-skin cancer and second most common cause of cancer deaths among women in the USA. There is ample prospective evidence that lumpectomy followed by breast radiation therapy allows breast preservation with no compromise in overall survival (1-3).
With any form of radiation therapy, damage to adjacent normal tissues often limits the dose that can be applied to the tumor. Relevant complications after conventional radiotherapy for breast cancer are pulmonary complications (radiation pneumonitis, fibrosis), ischemic heart disease, skin fibrosis and fat necrosis (4-7). An alternative or superior irradiation technique must offer significant reduction in toxicity while maintaining loco-regional control and overall survival.
Over the last decade, partial breast high dose brachytherapy has become an alternative management option for patients with Stage I and Stage II breast cancer. Features such as highly conformal therapy, avoidance of sensitive structures (which reduces the risk of toxicities), and the shortened course of treatment have attracted the attention of physicians and patients.
Brachytherapy physics and technology have made significant improvements (8, 9) , providing safe, fast and userfriendly source delivery (afterloading) and dose checking. High dose-rate (HDR) brachytherapy requires highly trained professionals for safety and delivery. Invasive catheter placement and consequent cosmetic effects are concerns for many patients who go through this treatment.
Excessive lung, skin and heart dose can have serious side effects for standard breast-conserving external beam radiation therapy (EBRT) for early stage breast cancer management. The protracted course of EBRT, 5-7 weeks, has led several investigators to evaluate HDR brachytherapy since it offers a significantly shorter overall time. With proper patient selection, the clinical results of brachytherapy (10-12) are very promising, although a proportion of patients suffer fat necrosis which is painful and requires surgical removal (13) . The helical tomotherapy option can also be given in a shorter overall time, while still offering high conformality in target irradiation and reduced probability of adverse effects.
The potential advantages of conformal EBRT partial-breast irradiation, compared to HDR brachytherapy, include elimination of an additional surgical procedure, improved dose homogeneity within the target volume, and lower doses to tissues outside the tumor. With 3D conformal radiotherapy and intensity-modulated radiotherapy (IMRT), it is possible to optimize the delivery of radiation to complex target volumes (14, 15) sparing normal and sensitive organs surrounding the tumor. An advantage of these techniques is the substantial reduction of normal tissue receiving high dose, with a possibility of increasing dose to the target volume. This might allow the overall treatment course to be shortened without compromising tumor control or increasing toxicities to normal tissues in a fashion similar to HDR brachytherapy. The application of advanced external beam techniques is an attractive option for partial breast treatment (16-19) with conformal and homogeneous dose delivery. However, the technique has not yet been universally embraced due to geometric uncertainty related to patient position, lumpectomy (soft tissue) image localization and subsequent possible inhomogeneity of dose delivered to the breast. Breast anato-my, especially in the supine position, makes it more difficult to exploit the advantages of IMRT treatment. There is a danger in using IMRT and conformal target radiation without a proper image localization of the target; underdosing the target could lead to recurrence (20).
Helical tomotherapy (21-26) is a recent technological advancement that provides MVCT-based image-guidance and intensity modulated adaptive radiotherapy, which has the potential for (but is not yet clinically available) dose verification followed by dose modification where necessary. We conducted a study to compare and explore helical tomotherapy as an alternative treatment modality for patients requiring partial breast irradiation. We present here a detailed comparison of helical tomotherapy planning and an HDR brachytherapy CT-based treatment plan with individual anatomical dose coverage for sensitive organs. In addition, we also compared our results with another emerging technology, 3D conformal external beam partial breast irradiation as described by Baglan et al. (15) .
Methods and Materials
A T1 N0 breast cancer patient treated with HDR breast brachytherapy after lumpectomy was selected for the current planning study. With the help of a template guide and an in situ CT scan, twenty-five brachytherapy needles were placed in the prone patient's breast, adequately covering the target volume. Target (PTV) was defined as lumpectomy cavity plus a 20 mm margin. The target contour was modified to give an adequate margin (∼5mm) below the skin and above the pectoralis muscle. A CT scan with the patient in a prone position was taken along with opaque dummy sources inserted into each individual implanted plastic catheter. The patient was laid prone on the customized position-supporting mattress in such way that the affected breast with dummy needles hung freely. During the CT scan, all the needles were marked and a digital photo was taken to correlate and track all of the needles during the HDR brachytherapy planning.
Brachytherapy Planning
The Nucletron PLATO planning station was used for contouring and HDR brachytherapy planning. The PLATO planning system follows the recommendation of AAPM Task Group 43 (27) for dose calculations. CT-based contouring was done for the lumpectomy bed, target (PTV), lung, skin, pectoralis muscle, chest wall and heart. The prescription dose was 34 Gy (10 fx of 3.4 Gy, BID over 5 days). Graphical and weight optimization (duration of the presence of each source in the breast) were used to enclose the target with the 100% isodose line. DVHs were generated for the target volume and all of the sensitive organs. Average doses were derived from the DVH for the target and all the sensitive organs. The duration of each treatment delivery was approximately half an hour.
Tomotherapy Planning
The DICOM CT images taken in the GE scanner were sent to the helical tomotherapy planning workstation along with the same contours for target, lung, skin, pectoralis muscle, chest wall and heart. A small portion of the body image (dorsal) was lost due to the limited field of view of the CT scanner. This portion of the CT was contoured and blocked out during the treatment planning process (by using the directional blocking function). The tomotherapy plan excluded that blocked region from calculations to reduce the uncertainty in dose calculations and the optimized plan did not deliver direct radiation to that region. The tomotherapy prescription dose was 34 Gy (10 fx of 3.4 Gy, BID in 5 days), to assure proper comparison to HDR brachytherapy or accelerated EBRT (15).
The tomotherapy treatment planning system (Hi-Art System 2.0) was used for the IMRT treatment planning with a 6MV photon beam. The optimization calculation is based on the superposition and convolution method (26). PTV coverage was adjusted to a 95% isodose line. The pitch and modulation factor (MF) used were 0.21 and 1.8, respectively (28) and the slice width (distance between two jaws in the superior and inferior direction projected to the isocenter) used was 2.5 cm to achieve good isodose coverage to the target within a reasonable treatment delivery time of 7 minutes. Maximum importance was given to PTV dose coverage and homogeneity: soft constraints such as minimum dose and penalty, maximum dose and penalty, and DVH dose and penalty were adjusted accordingly during optimization. Cumulative DVHs were analyzed for the target, lung, heart, skin, pectoralis muscle and chest wall. With MVCT image-guidance, the estimated total time required would be approximately 15 minutes from set-up to completion of the dose delivery.
The process of registration of MVCT and planning CT was demonstrated. A patient underwent contrast enhanced conventional pretreatment CT imaging followed by non-contrast enhanced MVCT in the same position, using helical tomotherapy at a dose of under 2 cGy. MVCT and conventional kilovoltage (kVCT) images were fused to correlate the anatomy seen from both methods.
Simulation of Left Breast Treatment
In order to estimate maximum cardiac dose (a "worst case scenario"), a simulation of a treatment to the left breast was carried out. A mirror image of the original heart contour was drawn on the CT image from the right breast case, such that the heart volume, density and distance from the tumor bed were reproduced for the simulated left breast case.
Tomotherapy, brachytherapy and accelerated EBRT planning were done with these simulated CT images to estimate dose to the heart resulting from all three methods.
Results
The results of the prone breast helical tomotherapy treatment planning are shown in Figure 1 . The DVH for the target and for the critical organs (i.e., lung, skin, muscle and heart), are shown in the top portion of Figure 1 . The isodose lines around the lumpectomy bed, target (PTV) and other sensitive organs are shown in three planes in the bottom of Figure  1 . Highly conformal and homogeneous dosimetric coverage of the target (PTV) was achieved in the tomotherapy treatment plan with a negligible "high dose tail". The tomotherapy plan kept the lung dose below 10Gy for both lungs and it reduced skin dose of the treated breast to 50% of the target dose at 20% dose volume level. The pectoral muscle dose was under 15Gy. As a consequence of directional blocking, a unique feature of tomotherapy planning optimization, the contralateral breast skin received negligible dose. A very sharp dose gradient was observed around the PTV in tomotherapy compared to brachytherapy. Detailed quantitative results comparing doses in tomotherapy with brachytherapy in various sensitive structures and PTV for a single fraction are listed in Table I . The higher doses to 1cc and 5cc volumes within the PTV are tabulated in order to demonstrate the different characteristics of dose fall-off (inhomogeneity including small hot spots). Results of planning following accelerated partial breast EBRT (15) are shown in Table II for the same prescription used in tomotherapy and brachytherapy. Breast skin and pectoral muscle doses were lower for tomotherapy than for EBRT. The lung, chest wall, and heart dose in EBRT were lower compared to tomotherapy and brachytherapy. In all three cases, dose variations in sensitive organs are small. Good anatomical contrast was observed in the kVCT, MVCT, and fusion images as shown in Figures 2a, 2b and 2c for transverse, sagital and coronal views respectively.
The DVH for the PTV, lumpectomy bed, and the critical organs for the brachytherapy plan are shown separately in the left panel of Figure 3 . The right panel of Figure 3 shows isodose lines on the prone breast transverse kVCT image. The dose (in cGy) shown is for one fraction. 150% isodose lines (white) surround the 192 Ir source. PTV coverage with HDR was very inhomogeneous. Maximum dose to the right lung was limited to a total of 10Gy. Doses to the breast, skin and pectoral muscles were all below 30Gy. Table I shows the summary of mean and higher dose coverage for the helical tomotherapy treatment plan for the same patient that was planned and treated with HDR brachytherapy. The doses are shown for the smallest (1 cc) "hot spot" and also for 5cc volumes. In both treatment plans, the prescribed dose was 34 Gy in ten fractions of 3.4 Gy to the PTV. In both plans the normal tissue doses were substantial only for skin and pectoral muscles and were significantly lower for tomotherapy than for brachytherapy in terms of high dose regions (hot spots). Also, average dose to skin and pectoral muscles is slightly less with helical tomotherapy. Other normal tissues received much lower doses and were similar for tomotherapy and brachytherapy.
In the tomotherapy plan the PTV received an average of 3.45 Gy with doses of 3.62 and 3.7 Gy covering 5 cc and 1 cc volumes respectively; these are 6% and 9% above the prescribed dose. Skin and pectoral muscles received average doses of 1.53 and 0.93 Gy respectively. In contrast, with HDR brachytherapy the PTV received an average dose of 4.93 Gy, with a dose of 8 Gy covering 5 cc and 11.5 Gy covering 1 cc, indicating that the dose distribution was very non-uniform. The skin and pectoral doses from brachytherapy averaged 1.52 and 1.12 Gy, not dissimilar to the tomotherapy plans. However, the dose covering 1cc
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Hui et al. and 5cc are much higher for breast skin in brachytherapy compared to tomotherapy. For brachytherapy, plastic catheters were planted with the help of a template guide having a preordained pattern or order with minimum 1 cm separation in the inferior-superior direction and 0.5 cm separation in the anterior-posterior direction, between two sources. To adequately cover the target area, one catheter had to be placed at the edge of the target, which is close to the breast skin. This resulted in high dose to the skin. Dose calculations used in brachytherapy planning followed TG43 (27) and did not include lung tissue density inhomogeneity correction. As a consequence, the brachytherapy lung dose calculation has greater uncertainty than tomotherapy planning where inhomogeneity correction is imbedded in the convolution dose calculation.
The skin and pectoral muscles received the only substantial doses for 5 cc volume, 60.7% and 50.4% of the prescription from tomotherapy and 77.1 and 61.8% from brachytherapy. Owing to the usual non-linearity of linear-quadratic dose equivalents, these lower doses in the tomotherapy plan would be relatively smaller still in terms of BED. The higher and non-uniform doses in the brachytherapy PTV, but not in the tomotherapy plan, are obvious. Overall, tomotherapy yielded either somewhat lower or similar doses to the normal tissues than brachytherapy. Table II shows the comparison for both of the above with an accelerated partial breast EBRT treatment plan (15), prescribed to 3.4 Gy. Homogeneity within the PTV is good as no area received more than 4% above prescribed dose. However the skin and pectoral muscles receive doses much higher than with either brachytherapy or tomotherapy, with doses (1 cc and 5 cc volumes respectively) being 92% and 86% for skin and 99% and 96% for pectoral muscles with conventional external beam treatments. Further, the average skin and pectoral muscle doses are 61% and 45% for external beam, much higher than the 45% for skin and 27-33% for pectoral muscles delivered by tomotherapy or brachytherapy.
Discussion
In this investigation we have assessed the ability to provide a highly conformal and homogeneous dose to the targeted area within the breast using helical tomotherapy in a fashion that may be applicable for accelerated partial breast irradiation. Accelerated partial breast irradiation using HDR brachytherapy and more recently 3-D conformal external beam radiation therapy is becoming increasingly popular as favorable clinical data accumulates. The advantages to the patient, a five-day course vs. a 5-7-week course are obvious. From our study it appears that helical tomotherapy may be able to provide a reasonable alternative means of delivering accelerated treatment and in some ways may have advantages over brachytherapy. Dosimetric coverage of the target in HDR brachytherapy (Fig. 3) is conformal but very inhomogeneous. Tumor control probability is expected to be similar for both tomotherapy and brachytherapy due to similar dose coverage to the tumor bed. The inevitable dose gradients in brachytherapy result in non-uniform dosage both within and outside target volumes. Several clinical cases are reported with fat necrosis after HDR brachytherapy, causing painful masses within the tissues encompassed by the implant volume. Wazer et al. (13) reported 27% of patients, treated with HDR brachytherapy, developed clinically significant fat necrosis at a median follow-up interval of 24 months. This correlated with larger volume implants, reflecting the number of source dwell positions and the volume of tissue exposed to fractional doses higher than 340 cGy. This dose inhomogeneity may be responsible for the observed fat necrosis in HDR brachytherapy but this has not been rigorously verified clinically.
Using conformal external beam radiation therapy, by confining treatment to the limited volume of breast tissue adjacent to the lumpectomy cavity, it appears possible to give larger doses per fraction, thereby reducing the overall treatment time to approximately one week instead of the standard 5-7 weeks of standard external beam breast radiation therapy, while still maintaining good tumor control and cosmetic results. Our simulation of an accelerated partial breast 3-D conformal technique of Baglan et al. (15) showed a reduced dose to the lung and heart as can be seen in Table II . Target dose homogeneity is similar for both the 3-D conformal technique and the helical tomotherapy technique. However, higher skin dose was observed in the 3-D conformal external beam plan. In addition, accurate dose delivery is a major concern in conformal external radiation treatment (20) . Geometric uncertainty in tumor localization and associated sensitive structures can lead to uncertainty in dose delivery and a loss of the therapeutic advantages of conformal therapy. Reduced skin dose compared to the 3-D conformal technique was achieved in tomotherapy through the inherent characteristics of helical IMRT delivery. More importantly, tomotherapy through megavoltage CT (MVCT) imaging facilitates better definition of the target and sensitive structures in situ and reduces uncertainty in daily localization, offering an appropriately shaped IMRT treatment volume. The onboard MVCT image guidance has significant advantages over other means of localization (e.g., EPID, ultrasound, fluoroscopy). Megavoltage CT images are (a) threedimensional, (b) are intrinsically designed to register and auto-fuse with kVCT images to reconfirm anatomy and support automatic patient localization and (c) are able to distinguish the contrast of soft tissue as shown in Figure 2 . Automatic kVCT-MVCT image fusion offers guidance for day-to-day patient setup adjustment (25) . A study of MVCT in lung cancer patients by Welsh et al. (29) showed that MVCT appears adequate in most cases for its intended purposes of providing image guidance for daily radiation treatments for lesions in the lung parenchyma. For breast radiotherapy, MVCT can allow monitoring of any breast edema developing during the course of radiation therapy. Preliminary investigations by Hui et al. and Welsh et al. (30) revealed possible undesirable dosimetric consequences of breast edema, including underdosing certain areas of the breast. Three-dimensional real time MVCT imaging during the course of treatment could alert physicians to any significant increase in breast volume, thereby allowing adjustments to reduce the likelihood of under-dosing the target. These intrinsic advantages of helical tomotherapy allow very conformal radiation treatment with high accuracy of dose delivery with less chance of geographical (target) miss. Therefore, proper target localization and conformal IMRT planning appears to be a reasonable alternative choice to other external beam approaches or HDR brachytherapy. The unique capacity of helical tomotherapy for MVCT-guided IMRT distinguishes it from other existing external beam radiation therapy techniques. It will be interesting to see how helical tomotherapy compares to newly emerging technology for image-guided IMRT with conventional linacs.
DVH analysis of helical tomotherapy showed conformal avoidance of sensitive structures that was comparable to brachytherapy. The mean biological lung dose, NTDmean, (corrected for 2 Gy per fraction) was 1.9 Gy with helical tomotherapy. This is well below the threshold NTDmean (10 Gy) for lung complications from breast irradiation reported by Kwa et al. (31) . Tomotherapy may thus potentially reduce complications such as pneumonitis. Although in our analysis, we confined ourselves to a comparison of helical tomotherapy to HDR brachytherapy and 3-D conformal external beam radiation therapy, another approach to breast brachytherapy uses the radioisotope-filled balloon catheter (Mammosite). While this approach has some distinct advantages (for example, a typical treatment time of 5-10 minutes, and relative technical ease compared to standard catheterbased HDR brachytherapy), in our experience it is more limited in its flexibility. For lesions close to the chest wall or surface, the lung or skin doses can be considerable and without much potential for dose-modification. Helical tomotherapy in contrast offers great flexibility in its ability to sculpt the dose-distribution around unusually shaped target volumes and conformally avoid sensitive structures such as the lungs. Other complications such as myositis and chest wall calcifications may be reduced using helical tomotherapy with the prone patient. Short-term, mild reactions to breast irradiation such as edema, erythema, macular-papular rashes and superficial skin ulcerations are expected to be the same for helical tomotherapy and HDR brachytherapy, but perhaps lower than with other external beam treatments due to decreased skin dose, although this awaits clinical confirmation. Long-term cardiac related complications were reported by Gagliardi et al. (32) to be considerable for left whole breast irradiation due to the proximity of the heart to the left breast. In our study we simulated a left breast irradiation to calculate the dose to the heart using different techniques. In the left breast helical tomotherapy simulation the mean biological heart dose, NTDmean, was less than 0.7 Gy and only 10% of the heart volume received between 0.7 and 1 Gy. This is unlikely to be clinically significant as the threshold dose for overt cardiac disease is estimated to be 18 Gy (corrected for 2 Gy dose fractions) to 20% to 100% heart volume. A similar analysis of left breast brachytherapy showed a 100% increase in the heart dose in the left breast compared to the right breast treatment calculation; the average dose increased from 0.6 Gy to 1.3 Gy. In the tomotherapy simulation, the dose received by the heart in the left breast simulation was similar to that of the right breast treatment plan. This was achieved by allowing the helical tomotherapy beamlets to preferentially deliver dose to the tumor excision site, reducing dose to the heart by spreading the dose to its 360 degrees of treatment. Again, the significance of this awaits clinical implementation; to date no reports of excess cardiotoxicity have been directly attributed to the low doses associated with breast brachytherapy. The tomotherapy treatment optimization algorithm also provides the option of completely blocking the heart or other critical structures if desired. It was found that the tomotherapy dose homogeneity was improved with lower pitch. Higher conformality, dose homogeneity to the target, dose reductions in critical tissues can be enhanced further with proper adjustments of jaw size, pitch and modulation factor (MF). The estimated time required for this breast treatment was 7 minutes. However, higher MF (compared to the MF used in the present plan) for better dose homogeneity and dose controls will proportionally increase treatment delivery time. Total treatment delivery time including MVCT imaging may then take about 15 minutes. This is still much less than the brachytherapy treatment delivery, which takes almost 30 minutes.
Helical tomotherapy therefore appears to be an efficient, as well as highly conformal means of delivering accelerated partial breast radiation therapy with the benefit of imageguidance and without the need for an invasive procedure.
Conclusions
Our results suggest that image-guided helical tomotherapy is an attractive alternative means of delivering accelerated partial breast external beam radiation therapy. The helical tomotherapy treatment plan dose coverage is highly conformal and unlike HDR brachytherapy, is also very homogeneous. It may be possible to give larger doses per fraction as reported here, thereby reducing the overall treatment time as in HDR brachytherapy and accelerated partial breast irradia-tion external beam techniques, while maintaining good tumor control and cosmetic effects. Such accelerated treatment with helical tomotherapy would not require the additional, potentially complicated, invasive procedure of catheter placement. Unlike other IMRT approaches or 3-D conformal radiation therapy, helical tomotherapy offers IMRT with intrinsic image-guidance and the possibility of adaptive radiotherapy through megavoltage CT imaging. These attractive features have set the stage for clinical investigation of accelerated partial breast irradiation using helical tomotherapy at our institution and several others.
